For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a genuine breakthrough . These novel therapies stabilize the transthyretin protein, halting its damaging build-up and alleviating the